

The molecular neurobiology of depression

Vaishnav Krishnan^{1,2} & Eric J. Nestler^{1,2,3}

Unravelling the pathophysiology of depression is a unique challenge. Not only are depressive syndromes heterogeneous and their aetiologies diverse, but symptoms such as guilt and suicidality are impossible to reproduce in animal models. Nevertheless, other symptoms have been accurately modelled, and these, together with clinical data, are providing insight into the neurobiology of depression. Recent studies combining behavioural, molecular and electrophysiological techniques reveal that certain aspects of depression result from maladaptive stress-induced neuroplastic changes in specific neural circuits. They also show that understanding the mechanisms of resilience to stress offers a crucial new dimension for the development of fundamentally novel antidepressant treatments.

About one in six individuals in the United States will succumb to clinical depression during their lifetime¹. Core symptoms include depressed mood, anhedonia (reduced ability to experience pleasure from natural rewards), irritability, difficulties in concentrating, and abnormalities in appetite and sleep ('neurovegetative symptoms')². In addition to mortality associated with suicide, depressed patients are more likely to develop coronary artery disease and type 2 diabetes³. Depression also complicates the prognosis of a host of other chronic medical conditions^{4,5}. The chronic, festering nature of depression contributes substantially to the global burden of disease and disability.

Despite the prevalence of depression and its considerable impact, knowledge about its pathophysiology is rudimentary compared with knowledge of other common chronic and potentially fatal multifactorial conditions, such as type 2 diabetes (Table 1). There are several explanations for this discrepancy. First and foremost, observing pathological changes within the brain remains markedly more difficult than for all other organs. Available techniques to document the aberrant function of brain circuits depend on either post-mortem studies, which have numerous limitations, or neuroimaging techniques, which rely on detecting changes in neuronal activity by using indirect markers of activation⁶. Although these approaches have provided important insights into candidate brain regions, simple increases or decreases in regional brain activity are probably insufficient to explain the complex array of symptoms caused by depression. Several animal models have also informed knowledge of the neural circuitry of depression, but there are important challenges to how information gained from these models should be interpreted (Box 1).

Second, most depression occurs idiopathically, and the limited understanding of its aetiology is reflected as a list of risk factors, such as stressful life events, endocrine abnormalities (hypothyroidism and hypercortisolism), cancers (such as pancreatic adenocarcinoma and breast tumours) and side effects of drugs (for example, isotretinoin for acne, and interferon- α for hepatitis C), among many others^{2,4,7}. Genetic association studies have not uncovered strong and consistent genetic risk modifiers⁸, perhaps because of the sheer heterogeneity of depressive syndromes^{2,9}. Thus, genuine 'depression genes', which can be used to generate disease models in mice (for example, those for Rett syndrome or familial Alzheimer's disease), have not yet been identified. Genetic predispositions are thought to interact with environmental risk factors, such as stressful life events, which can initiate depressive

episodes in some patients¹⁰. Still, the tendency to live in high-stress environments might also be partly heritable (as is the case for 'risk or sensation seekers')¹¹, emphasizing the strong genetic contribution to even 'environmentally precipitated' depressive episodes.

The official diagnosis of depression is subjective and rests on the documentation of a certain number of symptoms that significantly impair functioning for a certain duration². These diagnostic criteria overlap with other conditions such as anxiety disorders, which have substantial co-morbidity with depression^{12,13}. Therefore, two 'depressed' patients might have only one symptom in common⁷, and a manic episode in one patient — even later in life — switches the diagnosis to bipolar disorder, which is presumably a distinct pathophysiological entity. This symptom-based diagnostic approach poses obvious obstacles to the interpretation of genome-wide association studies, as well as neuroimaging and post-mortem investigations.

In this Review, we summarize the current state of knowledge of the neural and molecular mechanisms of depression. We focus on key leading hypotheses in the field, and examine their strengths and weaknesses critically in the light of recent preclinical and translational studies. We also highlight new insights that promise to extend the understanding of depression and improve its treatment.

Neural circuitry of depression

Several brain regions and circuits regulate emotion, reward and executive function, and dysfunctional changes within these highly interconnected 'limbic' regions have been implicated in depression and antidepressant action¹⁴ (Fig. 1). A large body of post-mortem^{7,15} and neuroimaging^{7,16} studies of depressed patients have reported reductions in grey-matter volume and glial density in the prefrontal cortex and the hippocampus, regions thought to mediate the cognitive aspects of depression, such as feelings of worthlessness and guilt. However, the published findings are not consistent and are often complicated by comorbid diagnoses and medication history, and there has been limited success in demonstrating any clear cause–effect relationships of these pathological changes.

In contrast to structural studies, experiments assessing brain function, such as functional magnetic resonance imaging (fMRI) or positron-emission tomography (PET), show that activity within the amygdala and subgenual cingulate cortex (Cg25, a subregion of prefrontal cortex) is strongly correlated with dysphoric emotions: indices of neuronal activity

¹Department of Psychiatry and ²Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. ³Fishberg Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA.

Table 1 | A systematic comparison of major depression and type 2 diabetes

| Criterion | Major depressive disorder | Type 2 diabetes |
|----------------------------|--|---|
| Lifetime risk | 1 in 6 | 1 in 3 |
| Diagnosis and monitoring | Subjective–qualitative: patients must show a depressed mood or anhedonia, as well as assorted other symptoms, for at least 2 weeks, and these symptoms must disrupt normal social and occupational functioning Patients monitored through standardized questionnaires | Objective–quantitative: diagnosis requires demonstration of an increased amount of serum glucose with classical signs (polyuria, polydipsia, obesity) or abnormal glucose tolerance (reflecting insulin resistance) Significant increases in HbA1C, a glycosylated haemoglobin, demonstrate long-standing poor glycaemic control |
| Aetiology and risk factors | Stressful life events (such as loss of loved ones or financial or professional crises) Genetic risk (heritability ≈ 40%) Disease genes unknown; can be idiopathic, a side effect of a drug (such as interferon- α or isotretinoin) or secondary to systemic illness (such as Cushing's syndrome or stroke, among many others) | Lifestyle factors (sedentary lifestyle, high-fat diet) Genetic risk (heritability ≈ 35%) Established disease genes (such as <i>PPARG</i> , <i>TCF7L2</i> or <i>KCNJ11</i>); can be iatrogenic (such as treatment with glucocorticoids or phenytoin) |
| Treatments | Monoamine reuptake inhibitors (such as tricyclic drugs, SSRIs, NRIs or SNRIs) Monoamine oxidase inhibitors (such as tranylcypromine) 'Atypical' agents (such as bupropion or mirtazapine) Electroconvulsive seizures Psychotherapy Deep brain stimulation Exercise promotes recovery | Insulin Sulphonylureas (such as tolbutamide) Meglitinides (such as repaglinide) PPAR- γ agonists (such as rosiglitazone) Biguanides (such as metformin) Glucosidase inhibitors (such as miglitol) Incretin (GLP1) mimetics (such as exenatide) Lifestyle changes (such as weight loss or exercise) |
| Pathogenesis | Abnormal activity of the HPA axis (hypercortisolism or hypocortisolism)? Alterations in neurotrophic signalling? Abnormal hippocampal neurogenesis? Deficits in brain reward processing? Abnormal cognitive styles (negative thinking)? | Obesity, sedentariness and genetic predisposition promote peripheral insulin resistance leading to pancreatic β -cell hyperplasia β -Cell dysfunction and failure ensues, leading to impaired glucose tolerance End-organ damage (nephropathy, neuropathy and angiopathy) occurs secondarily to hyperglycaemia, excessive protein glycation and aberrant intracellular signalling |

GLP1, glucagon-like peptide 1; HbA1C, haemoglobin A1C; HPA, hypothalamic–pituitary–adrenal axis; *KCNJ11*, potassium inwardly rectifying channel J11 gene; NRIs, selective noradrenaline reuptake inhibitors; *PPARG*, peroxisome-proliferator-activated receptor- γ gene; SNRI, serotonin–noradrenaline reuptake inhibitor; *TCF7L2*, transcription factor 7 like 2 gene.

within these regions are increased by transient sadness in healthy volunteers and are chronically increased in depressed individuals, reverting to normal levels with successful treatment^{7,13}. Inspired by these findings, it was shown that deep brain stimulation applied to the white matter tracts surrounding Cg25 produced a sustained remission of depressive symptoms in a small cohort of treatment-resistant patients (patients who failed to respond to several standard treatments)¹⁷. Deep brain stimulation, achieved through the stereotactic surgical placement of stimulating electrodes, has also provided an acute ameliorative effect on clinical ratings when applied to the nucleus accumbens (NAc)¹⁸, a striatal subregion that is important for reward and for hedonic deficits in depression¹⁹.

These forebrain networks are significantly modulated by monoamine projections from midbrain and brainstem nuclei (dopamine from the ventral tegmental area (VTA), serotonin from the dorsal raphe located in the periaqueductal grey area, and noradrenaline from the locus coeruleus). In addition to controlling alertness and awareness, these neurotransmitters modulate the salience of emotional stimuli. More recent studies have investigated the role of specific hypothalamic nuclei in mediating the neurovegetative signs of depression. However, we add a note of caution: although depressive symptoms are probably mediated by dysfunction in a diffuse series of neural networks, the field has often used a simplistic 'localization of function' approach to examine limbic substrates (for example, amygdala ≈ 'fear and anxiety', NAc ≈ 'reward'). Such artificial distinctions are of limited heuristic value and reflect limitations in the ability of current technologies to understand systems-level dysfunction.

The role of monoamines

The 'monoamine hypothesis' of depression, which posits that depression is caused by decreased monoamine function in the brain, originated from early clinical observations^{14,20}. Two structurally unrelated compounds developed for non-psychiatric conditions, namely iproniazid and imipramine, had potent antidepressant effects in humans

and were later shown to enhance central serotonin or noradrenaline transmission. Reserpine, an old antihypertensive agent that depletes monoamine stores, produced depressive symptoms in a subset of patients. Today's antidepressant agents offer a better therapeutic index and lower rates of side effects for most patients, but they are still designed to increase monoamine transmission acutely¹⁴, either by inhibiting neuronal reuptake (for example, selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine) or by inhibiting degradation (for example, monoamine oxidase inhibitors such as tranylcypromine). Although these monoamine-based agents are potent antidepressants²¹, and alterations in central monoamine function might contribute marginally to genetic vulnerability^{8,22}, the cause of depression is far from being a simple deficiency of central monoamines. Monoamine oxidase inhibitors and SSRIs produce immediate increases in monoamine transmission, whereas their mood-enhancing properties require weeks of treatment. Conversely, experimental depletion of monoamines can produce a mild reduction in mood in unmedicated depressed patients, but such manipulations do not alter mood in healthy controls²³. Moreover, studies with rodent stress models have shown that enhancements in dopamine and noradrenaline transmission can have maladaptive roles in stress-related disorders by strengthening memories of aversive life events^{24,25}.

It is now thought that acute increases in the amount of synaptic monoamines induced by antidepressants produce secondary neuroplastic changes that are on a longer timescale and involve transcriptional and translational changes that mediate molecular and cellular plasticity^{2,20}. As one example, the serotonin 5-HT_{1B} receptor interacts with a calcium-binding protein named p11, which was upregulated in cerebral cortex on chronic treatment with SSRIs and was also found to be downregulated in post-mortem cingulate cortex samples from depressed individuals²⁶. The brain-specific transgenic overexpression of p11 produced an antidepressant phenotype, implicating this SSRI-mediated upregulation of p11 as an important mechanism downstream of serotonin receptor activation. Chronically administered antidepressants have also been shown to

upregulate the transcription factor CREB (cyclic-AMP-response-element-binding protein), which is downstream of several serotonin and other stimulatory G-protein-coupled receptors, in the hippocampus; this effect has been validated in human post-mortem tissue and directly linked to antidepressant-like responses in animal models^{2,20}. By contrast, stress activation of CREB in NAC triggers depression-like responses, which underscores crucial region-specific actions of neurotransmitters and their downstream effectors that have not been incorporated into simplistic deficiency models¹⁹.


Monoamine-based antidepressants remain the first line of therapy for depression, but their long therapeutic delays and low (about 30%) remission rates²¹ have encouraged the search for more effective agents^{14,27}. The serotonin receptors involved in the action of SSRIs remain unknown, although selective agonists of the serotonin 5-HT₄ receptor produce rapid antidepressant effects in rodents (three

to four days)²⁸. Experiments on mice deficient in P-glycoprotein, a molecule in the blood–brain barrier that transports numerous drugs back into the bloodstream, have shown that several antidepressant agents, including the SSRI citalopram, are substrates for P-glycoprotein. Human polymorphisms in the gene encoding P-glycoprotein significantly alter antidepressant efficacy in depressed individuals²⁹, suggesting the value of such a pharmacogenetic approach when selecting antidepressant agents³⁰.

Neurotrophins and neurogenesis

Volumetric decreases observed in the hippocampus and other fore-brain regions in subsets of depressed patients have supported a popular hypothesis for depression involving decrements in neurotrophic factors — neurodevelopmentally expressed growth factors that also regulate plasticity within adult brain^{31,32}. These studies have focused

Box 1 | Preclinical models



Animal models of depression are evaluated for their aetiological validity: to be valid, depression-like behaviours need to be caused by the same aetiologies that trigger human depression. This is a challenging requirement, given the absence of definitive aetiologies for human depression. Current models gauge an animal's 'depression-related' responses to acute or chronic inescapable stress. These include the forced-swim test^{35,53,73}, which quantifies immobility in a water bath (proposed to be analogous to 'behavioural despair' observed in depression; see box figure, left). Other assays include measuring social interaction (decreases in which may model social withdrawal of depression-related conditions)^{25,39,79,95}, the learned-helplessness test (which measures the development of passive responses to inescapable foot shock)⁸⁴, and intracranial self-stimulation, an operant measure of the effort that an animal expends to stimulate brain reward circuits electrically^{14,23}. Several of these show pharmacological validity — that is, they are sensitive to acutely administered known antidepressant compounds^{14,99} — which permits the rapid screening of potentially new therapeutic agents. However, because more than half of all depressed individuals do not respond fully to available antidepressants²¹, the requirement for pharmacological validity is a circular argument that deserves reconsideration. Models that use an acute stress (for example, forced swimming) are better thought of as 'tests' of coping behaviour, and are limited in their ability to recapitulate a long-lived multidimensional syndrome such as depression. Efforts to create the latter are almost entirely limited to chronic stress models such as chronic social defeat or chronic mild stress, which are more technically challenging but show unique sensitivity to chronic and not acute antidepressant administration, comparable to the therapeutic delay

of 4–6 weeks that is required for all available antidepressant drugs to treat depression in humans². Animal models also have face validity, in which certain behavioural changes brought about by stress or genetic manipulation superficially resemble depressive symptoms. For instance, an animal's decreased sucrose intake after chronic stress is thought to model anhedonia²⁵.

These tests have been applied to the study of the molecular neurobiology of depression in three main ways. The most popular approach documents neuroplastic changes in brain regions after chronic stress and has revealed a role for structural, transcriptional and epigenetic changes in several brain regions (for example, those shown in Figs 1–3). These models can also be used to examine the behavioural effects of region-specific genetic manipulation, achieved through targeted genetic mutations in mice or virus-mediated gene transfer. The selective breeding of extreme populations within outbred rodents has also been used to generate stress-vulnerable or stress-resistant inbred strains (not shown)¹⁷. This approach is particularly valuable for quantitative trait locus (QTL) analyses, as well as for dissecting epigenetic contributions to responsiveness to stress²⁵. These behavioural assays can also be used to study biological mechanisms that underlie phenotypic variations in stress responses. For example, susceptibility to social defeat is mediated by increases in the electrical activity of dopamine-producing neurons in the ventral tegmental area (VTA)²⁵, whereas resistance to learned helplessness is mediated by induction of the gene encoding the transcription factor Δ FOSB in the periaqueductal grey (PAG) area⁸⁴ (see box figure, right). In these ways, preclinical models of depression have provided important insights into the pathophysiology of depression.

largely on the role of brain-derived neurotrophic factor (BDNF), which is expressed abundantly in adult limbic structures. Support for this 'BDNF hypothesis' has come from a large preclinical literature showing that several forms of stress reduce BDNF-mediated signalling in the hippocampus, whereas chronic treatment with antidepressants increases BDNF-mediated signalling^{2,31}. Similar changes have been observed in the post-mortem hippocampus of humans with depression³³, as well as in the concentrations of serum BDNF, the source of which remains controversial³¹.

More causal evidence for the antidepressant action of BDNF has come from experiments in rodents in which antidepressant effects were observed on direct infusion of BDNF into the hippocampus³⁴ and were blocked on the conditional or inducible knockout of the gene encoding BDNF from forebrain regions^{32,35}. However, more recent findings have necessitated a revision of this hypothesis. First, a substantial number of preclinical studies either have failed to show these patterns of changes induced by stress and by antidepressants, or have shown the opposite effects^{36,37}. Second, male mice with conditional forebrain deletions of BDNF or its receptor do not show depression-like behaviour^{35,38}. Third, in other regions — for example the VTA and NAc — BDNF exerts a potent pro-depressant effect: chronic stress increases the amount of BDNF within the NAc³⁹, and the direct infusion of BDNF into the VTA–NAc increases

depression-related behaviours^{25,40}, whereas a selective knockout of the gene encoding BDNF from this circuit has antidepressant-like effects³⁹. Finally, a single-nucleotide polymorphism (G196A; Val 66 → Met 66) in the gene encoding BDNF, which significantly impairs the intracellular trafficking and activity-dependent release of BDNF^{41,42} and decreases hippocampal volume^{41,43}, does not alter genetic vulnerability to depression^{8,44} (Fig. 2). In addition, recent studies suggest complex interactions between the BDNF G196A polymorphism, a polymorphism in the serotonin transporter gene, and stressful life events^{45–47}. Taken together, these results suggest that the current formulation of the BDNF hypothesis is too simplistic; BDNF-mediated signalling is involved in neuroplastic responses to stress and antidepressants, but these effects are both region-specific¹⁹ and antidepressant-specific³¹ and function in the background of other potent genetic and environmental modifiers.

A marked cellular effect of several, but not all, antidepressant treatments is the induction of adult hippocampal neurogenesis — the process by which neural progenitors of the hippocampal subgranular zone (SGZ) divide mitotically to form new neurons that differentiate and integrate into the dentate gyrus^{20,48}. Blockade of hippocampal neurogenesis inhibits the therapeutic-like effects of most antidepressant treatments in rodent models⁴⁸. Moreover, treatment with antidepressants, possibly through the actions of CREB or other transcriptional




Figure 1 | Neural circuitry of depression. Several brain regions are implicated in the pathophysiology of depression. **a**, Deep brain stimulation of the subgenual cingulate cortex (Cg25)¹⁷ or the nucleus accumbens (NAc)¹⁸ has an antidepressant effect on individuals who have treatment-resistant depression. This effect is thought to be mediated through inhibiting the activity of these regions either by depolarization blockade or by stimulation of passing axonal fibres. (Image courtesy of T. Schlaepfer and V. Sturm, University Hospital, Bonn, Germany.) **b**, Increased activity-dependent release of brain-derived neurotrophic factor (BDNF) within the mesolimbic dopamine circuit (dopamine-producing ventral tegmental area (VTA) to dopamine-sensitive NAc) mediates susceptibility to social stress²⁵, probably occurring in part through activation of the transcription factor CREB (cyclic-AMP-response-element-binding protein)²⁰ by

phosphorylation (P). **c**, Neuroimaging studies strongly implicate the amygdala (red pixels show activated areas) as an important limbic node for processing emotionally salient stimuli, such as fearful faces⁷. (Image courtesy of D. Weinberger, National Institute of Mental Health, Bethesda, Maryland.) **d**, Stress decreases the concentrations of neurotrophins (such as BDNF), the extent of neurogenesis and the complexity of neuronal processes in the hippocampus (HP), effects that are mediated in part through increased cortisol concentrations and decreased CREB activity^{2,14}. **e**, Peripherally released metabolic hormones in addition to cortisol, such as ghrelin⁹⁵ and leptin⁹⁶, produce mood-related changes through their effects on the hypothalamus (HYP) and several limbic regions (for example, the hippocampus, VTA and NAc). DR, dorsal raphe; LC, locus coeruleus; PFC, prefrontal cortex.

regulators^{2,20}, increases the amounts of several growth factors in the hippocampus that influence neurogenesis. These include BDNF (which promotes neuronal survival⁴⁹), as well as vascular endothelial growth factor (VEGF) and VGF, which themselves have antidepressant and pro-neurogenic properties in rodents^{50–52}. The mechanisms by which new neurons might restore mood are largely unknown. Activity-dependent increases in neurogenesis might increase activity propagation through hippocampal subfields⁵³ and allow hippocampal networks to adapt and learn new experiences⁵⁴. Indeed, this raises the possibility that the presence of intact neurogenesis during stressful episodes mediates maladaptive learning and thus promotes depressive sequelae. Whereas several types of stress reduce SGZ cell proliferation, decreased neurogenesis does not itself produce depression^{48,55}; rodents in which hippocampal neurogenesis has been ablated (through either irradiation^{55,56} or genetic techniques⁵⁷) do not show anxiety-related or depression-related behaviours.

Collectively, these studies highlight the weaknesses of attempts to generate a ‘unified theory’ of depression. Mechanisms that promote depressive symptoms in response to stress differ markedly between different neural circuits and can also be distinct from changes that underlie depression in the absence of external stress (‘endogenous depression’). In addition, neuroplastic events that are required for antidepressant efficacy need not function through the reversal of stress-induced plasticity², and might function through separate and parallel circuits.

Neuroendocrine and neuroimmune interactions

Early clinical studies identifying reproducible but small increases in serum glucocorticoid concentrations in depression^{58,59} fuelled significant interest in the role of a dysfunctional hypothalamic–pituitary–adrenal axis in the pathophysiology of depression. Physical or psychological stress increases serum glucocorticoid concentrations, and some depression-like symptoms can be produced in rodents by chronic administration of glucocorticoids⁶⁰. Excess glucocorticoids, through the activation of glucocorticoid receptors, can reduce SGZ proliferation rates and produce atrophic changes in hippocampal subregions⁶¹. This could contribute to the hippocampal volume reductions seen in depression. Patients with Cushing’s syndrome, who have extremely high concentrations of circulating cortisol, also show depressive features and atrophic changes in the hippocampus^{2,61}. Several metabolic abnormalities that are often associated with depression, such as insulin resistance and abdominal obesity, can be at least partly explained by an increase in glucocorticoids^{4,62}. Hypercortisolaemia in depression is manifested at several levels, including impaired glucocorticoid-receptor-mediated negative feedback⁶², adrenal hyper-responsiveness to circulating adrenocorticotrophic hormone (ACTH)⁵⁸ and hypersecretion of corticotropin-releasing factor⁶³, the hypothalamic activator of ACTH release from the pituitary^{2,64}. In line with these findings, glucocorticoid and corticotropin-releasing factor receptor antagonists are currently being tested in clinical trials²⁷.




Figure 2 | BDNF and depression — an example of the complexities of the molecular pathophysiology of depression. **a**, Post-mortem data from depressed humans show that depression is associated with a decrease in the amount of BDNF in the hippocampus³³ and an increase (of similar magnitude) in the NAc²⁵, an example of the regional specificity of depression-related neuroplastic changes. **b**, Neuronal secretion of BDNF occurs through regulated (activity-dependent) and constitutive secretory pathways. Regulated secretion is modulated by the interactions of proteins in the Golgi apparatus with the pro-domain of BDNF, the site of a single-nucleotide polymorphism (G196A) in humans that results

in the substitution of valine at amino-acid residue 66 with methionine. **c**, The Met-66-containing BDNF variant has impaired intracellular trafficking. Met-66 BDNF is not properly sorted within the cell, causing it to be distributed throughout the cell body outside of vesicles⁴². In addition, less BDNF is secreted from the nerve terminal. **d**, Knock-in mice that homozygously express Met-66 BDNF⁴¹ have normal responses in the forced-swim test²⁵, but these mice show more anxiety-like behaviour⁴¹ and greater resilience to behavioural and molecular changes after social defeat²⁵, implicating this BDNF polymorphism in the pathophysiology of psychological disorders that are influenced by stressful life events.

More recent studies suggest that hypercortisolaemia is almost exclusively a feature of very severe depressive episodes, such as are observed in an in-patient setting⁶⁵ or accompanied by psychotic symptoms (for example, hallucinations and delusions)^{2,9} in which glucocorticoid antagonists show some therapeutic efficacy⁶⁶. By contrast, atypical depression, a subtype characterized by hyperphagia and hypersomnia, seems to be associated with hypocortisolaemia^{65,67}, a phenomenon that is also observed in certain associated conditions such as fibromyalgia, chronic fatigue syndrome and post-traumatic stress disorder⁶⁸. The origins of such distinct glucocorticoid profiles might reflect the evolutionary trade-off between the catabolic and immunosuppressant effects of glucocorticoids: whereas high serum concentrations of glucocorticoids promote the mobilization of energy resources during stressful experiences, low glucocorticoid states allow an unobstructed immune system to combat infection or physical injury sustained during adverse encounters in the wild⁵⁹.

Cytokines, which are humoral mediators of innate and adaptive immunity, are also important modulators of mood. Cytokine receptors within the central nervous system are activated by both peripherally and centrally synthesized cytokines⁶⁹. Low doses of lipopolysaccharide or interleukin 1 (IL-1) produce 'sickness behaviour' in rodents (consisting of social withdrawal and decreased exploratory and sexual behaviour), brought about by the release of pro-inflammatory cytokines such as interferon- α , tumour necrosis factor- α (TNF- α), IL-6 and IL-1 β , which activate the hypothalamic-pituitary-adrenal axis and central monoamine systems⁷⁰. Roughly 30% of individuals treated with recombinant interferons develop depression as a side effect of treatment⁷¹. Clinical studies examining depression-associated increases in serum cytokine concentrations have been largely inconsistent⁷⁰. This suggests that immune activation is a signature of a small subset of depression cases, including those associated with autoimmune conditions such as rheumatoid arthritis, in which heightened system-wide inflammation can increase the risk of acute coronary events⁴ in addition to producing depressive mood changes.

Administration of cytokines such as interferon- α or IL-6 to rodents does not cause consistent depression-like features⁷⁰. Nevertheless, recent preclinical studies indicate that blocking pro-inflammatory cytokine-mediated signalling can produce antidepressant effects. Mice with targeted deletions of the gene encoding IL-6 (ref. 72) or those encoding the TNF- α receptors⁷³ show antidepressant-like behavioural phenotypes, and a centrally administered antagonist of the IL-1 β receptor reversed the behavioural and antineurogenic effects of chronic stress⁷⁴. Future studies of the 'cytokine hypothesis' must focus on elucidating the largely unknown neural circuitry involved in the behavioural effects of cytokines, and must more precisely delineate the intercellular interactions involved between brain macrophages (microglia), glia and neurons within this circuitry.

Epigenetic mechanisms

Among the several methods by which experience can produce long-lasting changes in protein availability and function, there has been considerable recent interest in epigenetic modifications in the pathophysiology of depression and antidepressant action. These modifications (Fig. 3) encompass covalent changes to DNA (for example, DNA methylation) and post-translational modifications of histone N-terminal tails (for example, acetylation and methylation), as well as non-transcriptional gene-silencing mechanisms (for example, micro-RNAs)⁷⁵. Given that these changes can be long-lasting, epigenetics has been invoked to explain several aspects of depression, including high discordance rates between monozygotic twins, individual differences among inbred rodents, the chronic relapsing nature of the illness, and the strikingly greater prevalence of depression in women¹¹. In essence, epigenetic changes offer a mechanism by which environmental experiences can modify gene function in the absence of DNA sequence changes, and they might help to explain largely inconsistent genetic association studies of depression, for example by undermining the transcriptional impact of DNA sequence polymorphisms due to epigenetic

modifications on those gene promoters¹¹. Although epigenetic changes have been implicated in numerous psychiatric conditions⁷⁵, the field of depression research has focused on two main chromatin-modifying processes. The first is DNA methylation (of cytosine), which seems to be important in the influence of maternal behaviour on adult emotional processing. Adult offspring of rats born to mothers with low rates of maternal licking and grooming show increased anxiety and reduced expression of glucocorticoid receptors within the hippocampus compared with offspring of mothers with high rates of maternal behaviours. This reduced expression of glucocorticoid receptors is mediated by increased methylation of the glucocorticoid receptor gene promoter (effectively repressing gene expression). This long-lasting 'molecular scar'⁷⁵ is established within the first week of life and is effectively reversed by cross-fostering⁷⁶. Interestingly, this increase in methylation was also reversed by the infusion of trichostatin A, a histone deacetylase (HDAC) inhibitor⁷⁷.

Histone acetylation, which is associated with transcriptional activation and decondensed chromatin, seems to be a key substrate for antidepressant action⁷⁸. Increased histone acetylation at the *Bdnf* promoter in the hippocampus was shown to be required for the ability of chronically administered imipramine to reverse certain deleterious effects of social defeat⁷⁹. Moreover, HDAC inhibitors show antidepressant-like effects in the social-defeat assay and other behavioural assays^{79,80}, and efforts are underway to develop more potent agents that are designed to target specific HDACs, such as HDAC5, a class II HDAC^{75,79}. The implications of these studies come with an important anatomical caveat: although inhibiting the actions of HDAC5 in the hippocampus seems to be therapeutically advantageous^{77,80}, mice that are globally deficient in HDAC5 are more vulnerable to social defeat⁸¹. Similarly, although imipramine increases HDAC5 expression in the hippocampus⁷⁹, it significantly reduces HDAC5 expression within the NAc⁸¹, further emphasizing the regional specificity of stress-related and antidepressant-related plasticity.

Current knowledge of the diversity of chromatin-modifying enzymes, and techniques to detect and quantify chromatin modifications genome-wide, is growing at an enormous pace. An important challenge in the clinical translation of these approaches will be to improve the technological ability to demonstrate causation by developing techniques to detect these modifications *in vivo*. Such techniques will allow researchers to examine, for the first time, region-specific chromatin measures associated with depression or antidepressant responses in humans.

Resilience-related research

Humans show a remarkable heterogeneity in their responses to stress and adversity: although a subset of depression cases can be causally attributed to stressful life events, these events in themselves raise only moderately the risk of developing depression¹⁰. In addition, reactive dysphoric states such as post-traumatic stress disorder only emerge in about 10–20% of trauma-exposed individuals⁸². Although a large body of research describes maladaptive neurobiological changes that occur after stressful exposures (such as decreased hippocampal neurogenesis and lower concentrations of BDNF, as discussed in the section 'Neurotrophins and neurogenesis'), relatively little attention has been devoted to understanding how most individuals adapt well — that is, are 'resilient' — in the face of adversity⁸³.

Animal models have recently been used to provide some neurobiological insight into these clinical observations. For example, by exploiting natural variations in the development of active escape in the learned-helplessness test, stress-induced upregulation of the transcription factor Δ FOSB (a stable, truncated protein product of the *Fosb* gene) in the midbrain periaqueductal grey nucleus was shown to promote a resilient phenotype. This effect was mediated through downregulating expression of substance P, a neuropeptide released during stress⁸⁴. A more recent report illustrated the role of mesolimbic dopamine-mediated signalling in emotional homeostatic mechanisms²⁵. By adapting the social-defeat model^{39,79} of depression to examine the variations in response to chronic stress⁸⁵, vulnerability to the development of social avoidance and other

deleterious sequelae was shown to be mediated by the increased excitability of VTA dopamine neurons and their subsequent increased activity-dependent release of BDNF onto NAc neurons. Resilient mice (which also show increased Δ FOSB concentrations⁸⁴) escaped this increase in VTA neuronal excitability by upregulating voltage-gated potassium channels, which functions as a molecular compensation to restore normal excitability and maintain low levels of BDNF-mediated signalling in the NAc. Other putative mechanisms of resilience have come from clinical and preclinical investigations. One involves the release of neuropeptide Y from locus coeruleus nerve terminals onto amygdala neurons, which promotes resilient behaviour^{83,86}. Interestingly, many of these studies report stable individual differences in stress responses among genetically inbred mice, strongly implicating non-genomic factors^{25,84,87}. As these mice are housed under identical environmental conditions as well, the findings indicate the likely importance of epigenetic mechanisms during development, a possibility that now requires direct investigation.

Gene expression profiling of stress-vulnerable and stress-resilient mice revealed distinct transcriptional profiles in the VTA and NAc¹⁹, and similar results have been obtained in the hippocampus with related methods⁸⁸. These findings suggest that resilient behaviour represents a distinct, active neurobiological process (not simply the absence of vulnerability)²⁵. Accordingly, a comprehensive understanding of such molecular mechanisms of allostasis (ongoing efforts to maintain homeostasis)⁶¹ has the potential to be harnessed for the development of new therapeutic agents. In these ways, the identification of antivulnerability processes will be an important alternative approach to improving knowledge about the neurobiology of stress and the pathophysiology of depression.

New insights

Although the hypotheses described here remain active areas of research, recent findings have sparked interest in neurobiological systems that were previously unexplored in depression. A dramatic example is the observation that sub-anaesthetic doses of intravenously infused ketamine

(a non-competitive NMDA (*N*-methyl-D-aspartate) glutamate receptor antagonist and psychotomimetic) produce a rapid but transient antidepressant effect on individuals with treatment-resistant depression⁸⁹. This effect suggests that depressive symptoms can be improved by altering the actions of glutamate, the major excitatory neurotransmitter in the brain. The antidepressant properties of ketamine have been recapitulated in animal tests of antidepressant action, such as the forced-swim test, in which the ability of ketamine to reduce immobility required intact signalling through AMPA receptors for glutamate⁹⁰ and was associated with increased concentrations of hippocampal BDNF protein⁹¹. Despite the limited evidence for dysfunction in specific glutamate systems in depression, the clinical effects of ketamine have inspired new lines of preclinical research to explore the underlying neural circuitry and downstream signalling, as well as to identify previously unidentified NMDA receptor modulators that could be targeted to achieve better side-effect profiles⁹².

In the past few years, there has also been an increased interest in examining interactions between traditional mood substrates and pathways involved in the control of feeding and metabolism²⁹. MCH (melanin-concentrating hormone)-containing neurons projecting from the lateral hypothalamus to several limbic regions including NAc provide an important orexigenic (pro-appetite) signal. Global decreases in MCH-mediated signalling⁹³, as well as local MCH antagonism within the NAc⁹⁴, produce antidepressant-like responses in several rodent models, generating tremendous interest in the antidepressant potential of selective MCH antagonists¹⁴, which might also curb the weight gain associated with a subset of depression¹⁹. In contrast to the pro-depressant actions of MCH, other peptides such as orexin and ghrelin might have an antidepressant role, particularly during conditions of low caloric intake⁹⁵. These and other studies illustrate the general theme that an animal's metabolic status greatly influences mood and motivation. Understanding the complex molecular interactions between peripheral metabolic signals (such as ghrelin⁹⁵ and leptin⁹⁶) and centrally released regulators of feeding and arousal (such as MCH,




Figure 3 | Epigenetic regulation in depression. The transcriptional potential of genes involved in neuroplastic responses to stress or antidepressant treatments can be regulated through chromatin-remodelling events catalysed by specific enzymes. **a**, The methylation of histones on specific lysine residues (for example, Lys 9 and Lys 27) is associated with condensed chromatin (heterochromatin) and is important in the repression of *Bdnf* expression in the hippocampus after social defeat⁷⁹. The pluses and minuses indicate activation or inhibition, respectively, of a particular process. **b**, By contrast, repression of other genes can occur through the methylation of cytosine within CpG islands of promoter regions, attracting proteins involved in transcriptional

repression, such as SIN3A, MeCP2 (methyl-CpG binding protein 2) and histone deacetylases (HDACs). DNA methylation of the promoter of the glucocorticoid receptor gene occurs in rat pups born to mothers with inherently low levels of maternal behaviour⁷⁷. Although such methylation events have been reported to be reversible, the enzymes responsible for demethylating DNA have yet to be identified^{75,76}. **c**, Histone acetylation, catalysed by histone acetyltransferases, is associated with decondensed chromatin (euchromatin), increasing the activity of transcriptional complexes. HDAC inhibitors (which activate the expression of numerous genes that have not yet been identified with certainty) show antidepressant properties in several assays^{79,80}. Ac, acetyl; Me, methyl.

orexin, neuropeptide Y⁸³ and α -melanocyte-stimulating hormone⁹⁷) might provide new pathophysiological and therapeutic insights into mood disorders.

Conclusion

Knowledge of the pathophysiology of depression has evolved substantially: from Galen's speculations in antiquity about an excess of black bile ('*melancholia*')^{2,9} to theories focused on 'psychic pain' and 'chemical imbalances', and then to more current hypotheses that incorporate gene-environment interactions, endocrine, immunological and metabolic mediators, and cellular, molecular and epigenetic forms of plasticity. However, enormous gaps in the knowledge of depression and its treatment persist. Instead of being overwhelmed by the heterogeneity of the illness, researchers and clinicians must embrace the polysyndromic nature of depression and use a multidisciplinary approach to explore the neurobiological bases for depression's many subtypes. To improve the still-low remission rates²¹, it will be imperative to look beyond monoamine and neurotrophic mechanisms¹⁴ and expand knowledge about antidepressant pharmacogenetics. Researchers must better understand the biological basis for the efficacy of deep brain stimulation in depression, and must explore the therapeutic possibilities of viral-mediated gene delivery, which is being applied successfully to other neuropsychiatric disorders⁹⁸. Finally, the field must harness the full potential of preclinical studies by continuing to develop improved animal models that incorporate the powerful array of molecular and anatomical tools available today, and must follow a systems approach to the study of depression that acknowledges the powerful bidirectional interactions between peripheral organs and the brain. ■

- Kessler, R. C. *et al.* Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch. Gen. Psychiatry* **62**, 593–602 (2005).
- Nestler, E. J. *et al.* Neurobiology of depression. *Neuron* **34**, 13–25 (2002).
- Knol, M. J. *et al.* Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. *Diabetologia* **49**, 837–845 (2006).
- Evans, D. L. *et al.* Mood disorders in the medically ill: scientific review and recommendations. *Biol. Psychiatry* **58**, 175–189 (2005).
- Gildengers, A. G. *et al.* Medical burden in late-life bipolar and major depressive disorders. *Am. J. Geriatr. Psychiatry* **16**, 194–200 (2008).
- Pelphs, E. A. & LeDoux, J. E. Contributions of the amygdala to emotion processing: from animal models to human behavior. *Neuron* **48**, 175–187 (2005).
- Drevets, W. C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. *Curr. Opin. Neurobiol.* **11**, 240–249 (2001).
- Lopez-Leon, S. *et al.* Meta-analyses of genetic studies on major depressive disorder. *Mol. Psychiatry* **13**, 772–785 (2007).
- Rush, A. J. The varied clinical presentations of major depressive disorder. *J. Clin. Psychiatry* **68** (Suppl. 8), 4–10 (2007).
- Kendler, K. S., Karkowski, L. M. & Prescott, C. A. Causal relationship between stressful life events and the onset of major depression. *Am. J. Psychiatry* **156**, 837–841 (1999).
- Mill, J. & Petronis, A. Molecular studies of major depressive disorder: the epigenetic perspective. *Mol. Psychiatry* **12**, 799–814 (2007).
- Hasler, G., Drevets, W. C., Manji, H. K. & Charney, D. S. Discovering endophenotypes for major depression. *Neuropsychopharmacology* **29**, 1765–1781 (2004).
- Ressler, K. J. & Mayberg, H. S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. *Nature Neurosci.* **10**, 1116–1124 (2007).
- Berton, O. & Nestler, E. J. New approaches to antidepressant drug discovery: beyond monoamines. *Nature Rev. Neurosci.* **7**, 137–151 (2006).
- Sheline, Y. I. Neuroimaging studies of mood disorder effects on the brain. *Biol. Psychiatry* **54**, 338–352 (2003).
- Harrison, P. J. The neuropathology of primary mood disorder. *Brain* **125**, 1428–1449 (2002).
- Mayberg, H. S. *et al.* Deep brain stimulation for treatment-resistant depression. *Neuron* **45**, 651–660 (2005).
This paper gives the first demonstration of the therapeutic efficacy of deep brain stimulation applied to the subgenual cingulate gyrus for treatment-refractory depression.
- Schlaepfer, T. E. *et al.* Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. *Neuropsychopharmacology* **33**, 368–377 (2008).
- Nestler, E. J. & Carlezon, W. A. Jr. The mesolimbic dopamine reward circuit in depression. *Biol. Psychiatry* **59**, 1151–1159 (2006).
- Pittenger, C. & Duman, R. S. Stress, depression, and neuroplasticity: a convergence of mechanisms. *Neuropsychopharmacology* **33**, 88–109 (2008).
- Trivedi, M. H. *et al.* Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am. J. Psychiatry* **163**, 28–40 (2006).
- Ansorge, M. S., Hen, R. & Gingrich, J. A. Neurodevelopmental origins of depressive disorders. *Curr. Opin. Pharmacol.* **7**, 8–17 (2007).
- Ruhe, H. G., Mason, N. S. & Schene, A. H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. *Mol. Psychiatry* **12**, 331–359 (2007).
- Hu, H. *et al.* Emotion enhances learning via norepinephrine regulation of AMPA-receptor trafficking. *Cell* **131**, 160–173 (2007).
- Krishnan, V. *et al.* Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. *Cell* **131**, 391–404 (2007).
This paper adapts the social-defeat model to study resilient behaviour and identifies active neurobiological mechanisms that maintain normal functioning in the face of chronic stress.
- Svenningsson, P. *et al.* Alterations in 5-HT_{1B} receptor function by p11 in depression-like states. *Science* **311**, 77–80 (2006).
- Mathew, S. J., Manji, H. K. & Charney, D. S. Novel drugs and therapeutic targets for severe mood disorders. *Neuropsychopharmacology* **33**, 2080–2092 (2008).
This paper provides an up-to-date and comprehensive list of new antidepressant drugs currently in various stages of clinical trials.
- Lucas, G. *et al.* Serotonin_{1A} (5-HT_{1A}) receptor agonists are putative antidepressants with a rapid onset of action. *Neuron* **55**, 712–725 (2007).
- Uhr, M. *et al.* Polymorphisms in the drug transporter gene *ABC1* predict antidepressant treatment response in depression. *Neuron* **57**, 203–209 (2008).
- Holsboer, F. How can we realize the promise of personalized antidepressant medicines? *Nature Rev. Neurosci.* **9**, 638–646 (2008).
- Duman, R. S. & Monteggia, L. M. A neurotrophic model for stress-related mood disorders. *Biol. Psychiatry* **59**, 1116–1127 (2006).
- Monteggia, L. M. *et al.* Essential role of brain-derived neurotrophic factor in adult hippocampal function. *Proc. Natl Acad. Sci. USA* **101**, 10827–10832 (2004).
- Karege, F., Vaudan, G., Schwald, M., Perroud, N. & La Harpe, R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. *Brain Res. Mol. Brain Res.* **136**, 29–37 (2005).
- Shirayama, Y., Chen, A. C., Nakagawa, S., Russell, D. S. & Duman, R. S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. *J. Neurosci.* **22**, 3251–3261 (2002).
- Monteggia, L. M. *et al.* Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. *Biol. Psychiatry* **61**, 187–197 (2007).
- Groves, J. O. Is it time to reassess the BDNF hypothesis of depression? *Mol. Psychiatry* **12**, 1079–1088 (2007).
- Martinovich, K., Manji, H. & Lu, B. New insights into BDNF function in depression and anxiety. *Nature Neurosci.* **10**, 1089–1093 (2007).
- Zorner, B. *et al.* Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than 'depressive'. *Biol. Psychiatry* **54**, 972–982 (2003).
- Berton, O. *et al.* Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science* **311**, 864–868 (2006).
By using the social-defeat model, this paper characterizes the potent, pro-depressant effects of BDNF in the mesolimbic dopamine pathway, which is opposite to the well-described antidepressant-like effects of BDNF in hippocampal circuits.
- Eisch, A. J. *et al.* Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. *Biol. Psychiatry* **54**, 994–1005 (2003).
- Chen, Z. Y. *et al.* Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. *Science* **314**, 140–143 (2006).
- Egan, M. F. *et al.* The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* **112**, 257–269 (2003).
This multidisciplinary study demonstrates how the polymorphism in BDNF in which methionine is substituted for valine at position 66 causes deficits in episodic memory, alters hippocampal activation and decreases activity-dependent BDNF secretion.
- Szeszko, P. R. *et al.* Brain-derived neurotrophic factor Val66Met polymorphism and volume of the hippocampal formation. *Mol. Psychiatry* **10**, 631–636 (2005).
- Gratacos, M. *et al.* Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. *Biol. Psychiatry* **61**, 911–922 (2007).
- Kaufman, J. *et al.* Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. *Biol. Psychiatry* **59**, 673–680 (2006).
- Kim, J. M. *et al.* Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders. *Biol. Psychiatry* **62**, 423–428 (2007).
- Pezawas, L. *et al.* Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. *Mol. Psychiatry* **13**, 709–716 (2008).
- Sahay, A. & Hen, R. Adult hippocampal neurogenesis in depression. *Nature Neurosci.* **10**, 1110–1115 (2007).
- Sairanen, M., Lucas, G., Ernfors, P., Castren, M. & Castren, E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. *J. Neurosci.* **25**, 1089–1094 (2005).
- Hunsberger, J. G. *et al.* Antidepressant actions of the exercise-regulated gene VGF. *Nature Med.* **13**, 1476–1482 (2007).
This paper characterizes the antidepressant effects of VGF, an exercise-regulated neurotrophic factor in the hippocampus, and identifies VGF-mediated signalling as a potential therapeutic target.
- Thakker-Varia, S. *et al.* The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. *J. Neurosci.* **27**, 12156–12167 (2007).
- Warner-Schmidt, J. L. & Duman, R. S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. *Proc. Natl Acad. Sci. USA* **104**, 4647–4652 (2007).
- Airan, R. D. *et al.* High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. *Science* **317**, 819–823 (2007).
This study uses quantitative voltage-sensitive dye imaging to explore the contribution of antidepressant-induced neurogenesis to local hippocampal network dynamics.
- Kempermann, G. The neurogenic reserve hypothesis: what is adult hippocampal neurogenesis good for? *Trends Neurosci.* **31**, 163–169 (2008).
- Surget, A. *et al.* Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. *Biol. Psychiatry* **64**, 293–301 (2008).
- Santarelli, L. *et al.* Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* **301**, 805–809 (2003).
- Zhao, C., Deng, W. & Gage, F. H. Mechanisms and functional implications of adult neurogenesis. *Cell* **132**, 645–660 (2008).

58. Parker, K. J., Schatzberg, A. F. & Lyons, D. M. Neuroendocrine aspects of hypercortisolism in major depression. *Horm. Behav.* **43**, 60–66 (2003).
59. Raison, C. L. & Miller, A. H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am. J. Psychiatry* **160**, 1554–1565 (2003).
60. Gourley, S. L. *et al.* Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. *Biol. Psychiatry* **63**, 353–359 (2007).
61. McEwen, B. S. Physiology and neurobiology of stress and adaptation: central role of the brain. *Physiol. Rev.* **87**, 873–904 (2007).
62. Brown, E. S., Varghese, F. P. & McEwen, B. S. Association of depression with medical illness: does cortisol play a role? *Biol. Psychiatry* **55**, 1–9 (2004).
63. Nemeroff, C. B. & Owens, M. J. Treatment of mood disorders. *Nature Neurosci.* **5** (Suppl.), 1068–1070 (2002).
64. de Kloet, E. R., Joels, M. & Holsboer, F. Stress and the brain: from adaptation to disease. *Nature Rev. Neurosci.* **6**, 463–475 (2005).
65. Brouwer, J. P. *et al.* Thyroid and adrenal axis in major depression: a controlled study in outpatients. *Eur. J. Endocrinol.* **152**, 185–191 (2005).
66. Schatzberg, A. F. & Lindley, S. Glucocorticoid antagonists in neuropsychotic disorders. *Eur. J. Pharmacol.* **583**, 358–364 (2008).
67. Gold, P. W. & Chrousos, G. P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. *Mol. Psychiatry* **7**, 254–275 (2002).
68. Heim, C., Ehler, U. & Hellhammer, D. H. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. *Psychoneuroendocrinology* **25**, 1–35 (2000).
69. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nature Rev. Neurosci.* **9**, 46–56 (2008).
70. Dunn, A. J., Swiergiel, A. H. & de Beaurepaire, R. Cytokines as mediators of depression: what can we learn from animal studies? *Neurosci. Biobehav. Rev.* **29**, 891–909 (2005).
71. Loftis, J. M. & Hauser, P. The phenomenology and treatment of interferon-induced depression. *J. Affect. Disord.* **82**, 175–190 (2004).
72. Chourbaji, S. *et al.* IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. *Neurobiol. Dis.* **23**, 587–594 (2006).
73. Simen, B. B., Duman, C. H., Simen, A. A. & Duman, R. S. TNF α signaling in depression and anxiety: behavioral consequences of individual receptor targeting. *Biol. Psychiatry* **59**, 775–785 (2006).
74. Koo, J. W. & Duman, R. S. IL-1 β is an essential mediator of the antineurogenic and anhedonic effects of stress. *Proc. Natl Acad. Sci. USA* **105**, 751–756 (2008).
75. Tsankova, N., Renthal, W., Kumar, A. & Nestler, E. J. Epigenetic regulation in psychiatric disorders. *Nature Rev. Neurosci.* **8**, 355–367 (2007).
76. Szyf, M., Weaver, I. & Meaney, M. Maternal care, the epigenome and phenotypic differences in behavior. *Reprod. Toxicol.* **24**, 9–19 (2007).
77. Weaver, I. C. *et al.* Epigenetic programming by maternal behavior. *Nature Neurosci.* **7**, 847–854 (2004).
78. Tsankova, N. M., Kumar, A. & Nestler, E. J. Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. *J. Neurosci.* **24**, 5603–5610 (2004).
79. Tsankova, N. M. *et al.* Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. *Nature Neurosci.* **9**, 519–525 (2006).
This paper contains one of the first demonstrations of the role of epigenetic modifications in stress-induced effects on the brain and their reversal by antidepressant treatments, as well as the therapeutic potential of HDAC inhibitors in depression.
80. Schroeder, F. A., Lin, C. L., Crusio, W. E. & Akbarian, S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. *Biol. Psychiatry* **62**, 55–64 (2007).
81. Renthal, W. *et al.* Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. *Neuron* **56**, 517–529 (2007).
82. Yehuda, R. Risk and resilience in posttraumatic stress disorder. *J. Clin. Psychiatry* **65** (Suppl. 1), 29–36 (2004).
83. Charney, D. S. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. *Am. J. Psychiatry* **161**, 195–216 (2004).
84. Berton, O. *et al.* Induction of Δ FosB in the periaqueductal gray by stress promotes active coping responses. *Neuron* **55**, 289–300 (2007).
In this paper, the learned-helplessness model is used to illustrate the pro-resilient effects of the transcription factor Δ FosB within the dorsal raphe nucleus.
85. Strekalova, T., Spanagel, R., Bartsch, D., Henn, F. A. & Gass, P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. *Neuropsychopharmacology* **29**, 2007–2017 (2004).
86. Sajdyk, T. J. *et al.* Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. *J. Neurosci.* **28**, 893–903 (2008).
87. Peaston, A. E. & Whitelaw, E. Epigenetics and phenotypic variation in mammals. *Mamm. Genome* **17**, 365–374 (2006).
88. Bergstrom, A., Jayatissa, M. N., Thykjaer, T. & Wiborg, O. Molecular pathways associated with stress resilience and drug resistance in the chronic mild stress rat model of depression: a gene expression study. *J. Mol. Neurosci.* **33**, 201–215 (2007).
89. Zarate, C. A. Jr *et al.* A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Arch. Gen. Psychiatry* **63**, 856–864 (2006).
90. Maeng, S. *et al.* Cellular mechanisms underlying the antidepressant effects of ketamine: role of α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. *Biol. Psychiatry* **63**, 349–352 (2008).
91. Garcia, L. S. *et al.* Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **32**, 140–144 (2008).
92. Maeng, S. & Zarate, C. A. Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. *Curr. Psychiatry Rep.* **9**, 467–474 (2007).
93. Roy, M., David, N., Cueva, M. & Giorgetti, M. A study of the involvement of melanin-concentrating hormone receptor 1 (MCHR1) in murine models of depression. *Biol. Psychiatry* **61**, 174–180 (2007).
94. Georgescu, D. *et al.* The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. *J. Neurosci.* **25**, 2933–2940 (2005).
95. Lutter, M. *et al.* The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. *Nature Neurosci.* **11**, 752–753 (2008).
96. Lu, X. Y., Kim, C. S., Frazer, A. & Zhang, W. Leptin: a potential novel antidepressant. *Proc. Natl Acad. Sci. USA* **103**, 1593–1598 (2006).
97. Kishi, T. & Elmquist, J. K. Body weight is regulated by the brain: a link between feeding and emotion. *Mol. Psychiatry* **10**, 132–146 (2005).
98. Kapliot, M. G. *et al.* Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. *Lancet* **369**, 2097–2105 (2007).
This paper demonstrates the efficacy and safety of stereotactic viral-mediated gene therapy in the treatment of severe Parkinson's disease.
99. Cryan, J. F., Markou, A. & Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. *Trends Pharmacol. Sci.* **23**, 238–245 (2002).

Acknowledgements Work in E.J.N.'s laboratory was supported by grants from the National Institute of Mental Health.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare competing financial interests: details accompany the full-text HTML version of the paper at www.nature.com/nature. Correspondence should be addressed to E.J.N. (eric.nestler@mssm.edu).